Therefore, up-to-date clinical data allow us to conclude that so-called “low-dose” IL-2 appropriately administered in the treatment of autoimmune diseases should not surpass 3 × 106 IU/day, and the cumulative dose should not exceed more than 50–100 × 106 IU for a course of therapy. The gene discussed is IL2; the disease is autoimmune disease.